1-7 of 7
Ju-hee Bang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dynamics and Characteristics of BCR-ABL1 Multiple Mutations in Tyrosine Kinase Inhibitor Resistant CML

Soo-Hyun Kim, Soo Young Choi, Sung-Eun Lee, Ju-Hee Bang, Ji-Young Byeun, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Saengsuree Jootar, Dong-Wook Kim
Journal: Blood
Blood (2012) 120 (21): 1677.
https://doi.org/10.1182/blood.V120.21.1677.1677
Published: 2012
Journal Articles

Comparison of Sokal, Hasford and EUTOS Scores in Terms of Long-Term Treatment Outcome According to the Risks in Each Prognostic Model: A Single Center Data Analyzed in 255 Early Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib Mesylate.

Seung-Ah Yahng, Eun-Jung Jang, Soo Young Choi, Yun-Jung Oh, Ju-Hee Bang, Jin-Eok Park, Hye-Lim Jeon, Sung-Eun Lee, Soo-Hyun Kim, Ji-Young Byun, Dong-Wook Kim
Journal: Blood
Blood (2012) 120 (21): 2794.
https://doi.org/10.1182/blood.V120.21.2794.2794
Published: 2012
Journal Articles

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Soo-Young Choi, Sung-Eun Lee, Soo-Hyun Kim, Eun-Jung Jang, Jin-hwa Lee, Yun-Jung Oh, Ju-Hee Bang, Jin-Eok Park, Ji-Young Byun, Hye-Lim Jeon, Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, Hyeoung-Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung-Hyun Kim, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim
Journal: Blood
Blood (2012) 120 (21): 3775.
https://doi.org/10.1182/blood.V120.21.3775.3775
Published: 2012
Journal Articles

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

Clinical Trials & Observations
Susan Branford, David T. Yeung, Jodi A. Prime, Soo-Young Choi, Ju-hee Bang, Jin Eok Park, Dong-Wook Kim, David M. Ross, Timothy P. Hughes
Journal: Blood
Blood (2012) 119 (18): 4264–4271.
https://doi.org/10.1182/blood-2011-11-393041
Published: 2012
Includes: Supplemental data
Journal Articles

Discontinuation of Imatinib Therapy in Chronic Myeloid Leukemia Patients with Sustained Complete Molecular Response 4.5 (CMR 4.5 )

Hyun-Gyung Goh, Soo-Young Choi, Ju-Hee Bang, Soo-Hyun Kim, Eun-Jung Jang, Dongho Kim, Ji-Young Byeun, Joon Seong Park, Hyeoung-Joon Kim, Hawk Kim, Dong-Wook Kim
Journal: Blood
Blood (2011) 118 (21): 2763.
https://doi.org/10.1182/blood.V118.21.2763.2763
Published: 2011
Journal Articles

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

Hyun-Gyung Goh, Saengsuree Jootar, Hyeoung-Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung Hyun Kim, Dae Young Zang, Suk-Joong Oh, Soo-Young Choi, Ju-Hee Bang, Soo-Hyun Kim, Eun-Jung Jang, Sung-Eun Lee, Dongho Kim, Ji-Young Byeun, Richard C. Woodman, Tomasz Szczudlo, Hee Jung Kim, Dong-Wook Kim
Journal: Blood
Blood (2011) 118 (21): 2765.
https://doi.org/10.1182/blood.V118.21.2765.2765
Published: 2011
Journal Articles

Correlation of Molecular Response At 18 Month with Survival Benefits As Response-Related Prognostic Factor

Soo-Hyun Kim, Dongho Kim, Hyun-Gyung Goh, Soo-Young Choi, Ju-Hee Bang, Ji-Young Byeun, Dong-Wook Kim
Journal: Blood
Blood (2011) 118 (21): 2766.
https://doi.org/10.1182/blood.V118.21.2766.2766
Published: 2011